Enanta Pharmaceuticals Inc(9EP)

Description: Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

---

Keywords: Biotechnology Hepatitis Liver Disease Hepatitis C HCV Cyclopropanes Viral Infections Hbv Pyrrolidines Carbamates Macrocycles Protease Inhibitor Asunaprevir Glecaprevir/Pibrentasvir Paritaprevir Treatment Of Viral Infections And Liver Diseases

---

Home Page: www.enanta.com

500 Arsenal Street
Watertown, MA 02472
United States
Phone: 617 607 0800

---

Officers

Exchange: F

Country: DE : Germany

Currency: Euro (€)